Diana Chan

Dr. Diana Chan


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Allergies
Verified
Journal Article
Open access
PDF file
TSTravis Satnarine
Travis Satnarine
AAAlana Xavier De Almeida
Alana Xavier De Almeida
MWMalaika Woody
Malaika Woody
KCKrisia Banegas Carballo
Krisia Banegas Carballo
DCDiana Chan
Diana Chan
MGMelissa Gans
Melissa Gans
Peanut allergy, a significant public health issue, poses challenges due to its potential for life-threatening anaphylaxis and profound impact on quality of life. Traditional management approaches, including allergen avoidance and epinephrine administration, are effective in mitigating acute symptoms but do not address the underlying allergy or long-term disease burden. Recent advances in immunotherapy and biologics, as well as innovative technologies such as gene editing and microbiome modulation, have introduced promising pathways for desensitization and sustained unresponsiveness. This review provides a comprehensive exploration of emerging therapies for peanut allergy, including oral, sublingual, and epicutaneous immunotherapy, biologic agents, gene-editing techniques, and novel drug therapies. We discuss their mechanisms, clinical efficacy, and associated challenges, emphasizing the potential for these innovations to revolutionize peanut allergy treatment. Despite significant progress, barriers such as adverse reactions, cost, and limited access remain. Addressing these challenges through further research and standardization could transform the future of peanut allergy management.

29 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TSTravis Satnarine
Travis Satnarine
AAAlana Xavier De Almeida
Alana Xavier De Almeida
MWMalaika Woody
Malaika Woody
KCKrisia Banegas Carballo
Krisia Banegas Carballo
DCDiana Chan
Diana Chan
MGMelissa Gans
Melissa Gans
Peanut allergy, a significant public health issue, poses challenges due to its potential for life-threatening anaphylaxis and profound impact on quality of life. Traditional management approaches, including allergen avoidance and epinephrine administration, are effective in mitigating acute symptoms but do not address the underlying allergy or long-term disease burden. Recent advances in immunotherapy, biologics, and innovative technologies such as gene editing and microbiome modulation have introduced promising pathways for desensitization and sustained unresponsiveness. This review provides a comprehensive exploration of emerging therapies for peanut allergy, including oral, sublingual, and epicutaneous immunotherapy, biologic agents, gene-editing techniques, and novel drug therapies. We discuss their mechanisms, clinical efficacy, and associated challenges, emphasizing the potential for these innovations to revolutionize peanut allergy treatment. Despite significant progress, barriers such as adverse reactions, cost, and limited access remain. Addressing these challenges through further research and standardization could transform the future of peanut allergy management.